Market capitalization | SEK2.33b |
Enterprise Value | SEK3.60b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 38.35 |
EV/Sales (TTM) EV/Sales | 1.65 |
P/S ratio (TTM) P/S ratio | 1.07 |
P/B ratio (TTM) P/B ratio | 0.85 |
Revenue growth (TTM) Revenue growth | -5.50% |
Revenue (TTM) Revenue | SEK2.18b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Bico Group forecast:
3 Analysts have issued a Bico Group forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,176 2,176 |
6%
6%
|
|
Gross Profit | 406 406 |
153%
153%
|
|
EBITDA | 100 100 |
149%
149%
|
EBIT (Operating Income) EBIT | -367 -367 |
52%
52%
|
Net Profit | -1,249 -1,249 |
37%
37%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cellink AB engages in the development and commercialization of bioprinting technologies. It prints 3D human organs and tissues for the development of pharmaceutical and cosmetic products. Its products include Inkredible, Bio X, Bio X6, Holograph X, Lumen X, and bioinks. The company was founded by Erik Gatenholm and Hector Daniel Martinez Avila in 2016 and is headquartered in Gothenburg, Sweden.
Head office | Sweden |
CEO | Maria Forss |
Founded | 2016 |
Website | bico.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.